MaxCyteMXCT +3.91%64 EV-to-FCF is -6.26 as of Jul. 12, 2026. GuruFocus rates MXCT with a GF Score™ of 64/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 416 Medical Devices & Instruments companies, MaxCyte ranks worse than 240384.38% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MaxCyte's Enterprise Value is $52.57 Mil.
MaxCyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.39 Mil. Therefore, MaxCyte's EV-to-FCF for today is -6.26.
The historical rank and industry rank for MaxCyte's EV-to-FCF or its related term are showing as below:
MXCT'
s EV-to-FCF Range Over the Past 10 Years
Min: -134.43 Med: -10.59 Max: 1.1
Current: -6.26
During the past 13 years, the highest EV-to-FCF of MaxCyte was 1.10. The lowest was -134.43. And the median was -10.59.
MXCT's EV-to-FCF is ranked worse than 100% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.355
vs MXCT: -6.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-12), MaxCyte's stock price is $1.325.
MaxCyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.370. Therefore, MaxCyte's PE Ratio (TTM) for today is At Loss.
MaxCyte (NAS:MXCT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MaxCyte's share price for today is $1.325.
MaxCyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MaxCyte EV-to-FCF Related Terms
MaxCyte EV-to-FCF Historical Data
* Premium members only.
The historical data trend for MaxCyte's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MaxCyte's EV-to-FCF falls into.
MaxCyte's current Enterprise Value is $52.57 Mil.
MaxCyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a EV-to-FCF of -6.26 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MaxCyte and its competitors. According to the industry distribution chart, MaxCyte ranks #999999 out of 416 companies in the Medical Devices & Instruments industry.
Is MaxCyte's EV-to-FCF too high?
MaxCyte's current EV-to-FCF is -6.26. Based on the distribution chart, MaxCyte ranks #999999 out of 416 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MaxCyte has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's EV-to-FCF compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #999999 out of 416 companies for EV-to-FCF. This places MaxCyte in the lower half of its industry. The industry median EV-to-FCF is 23.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.36, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current EV-to-FCF is -6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.33 — trading 48.4% below its estimated fair value. The current EV-to-FCF is -6.26. MaxCyte's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MaxCyte (MXCT), the current EV-to-FCF is -6.26 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.33 is trading 48.4% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
EV-to-FCF: -6.26
GF Value™: $2.57 vs. price of $1.33 (48.4% below fair value)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
64GF Score
Get the complete analysis for MXCT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
